{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:04:25Z","timestamp":1793714665507,"version":"4.6.1"},"reference-count":74,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mycobacterium abscessus (Mab) is a highly drug-resistant non-tuberculous mycobacterium that presents major treatment challenges, particularly in individuals with structural lung disease. Although historically considered ineffective, \u03b2-lactam antibiotics have gained renewed attention due to advances in \u03b2-lactamase inhibition and cell wall biology. This review synthesizes more than a decade of work, including in vitro susceptibility studies, biochemical characterization of Mab's \u03b2-lactamase (BlaMab) and peptidoglycans synthesis, and published clinical cases supporting the potential role of \u03b2-lactam-based regimens. We detail the enzymatic pathways involved in peptidoglycan cross-linking and the dual inhibition of D,D- and L,D-transpeptidases by select \u03b2-lactams, as well as the functional impact of inhibiting BlaMab. Novel \u03b2-lactamase inhibitors such as durlobactam may further enhance \u03b2-lactam efficacy. By integrating laboratory insights with clinical experience, this review provides a comprehensive perspective and informs ongoing efforts to design clinical trials repurposing \u03b2-lactam\/\u03b2-lactamase inhibitor combinations.<\/jats:p>","DOI":"10.1093\/cid\/ciaf547","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:53:12Z","timestamp":1758973992000},"page":"e135-e145","source":"Crossref","is-referenced-by-count":8,"title":["The Role of \u03b2-Lactam Antibiotics in Treating\n                    <i>Mycobacterium abscessus<\/i>\n                    : From Laboratory Insights to Clinical Applications and the Case for Clinical Trials"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3272-7231","authenticated-orcid":false,"given":"Khalid M","family":"Dousa","sequence":"first","affiliation":[{"name":"Louis Stokes Cleveland VA Medical Center, Case Western Reserve University , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Medicine, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjeong","family":"Shin","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland VA Medical Center, Case Western Reserve University , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Medicine, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian G","family":"Kurz","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, Yale School of Medicine , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5120-962X","authenticated-orcid":false,"given":"Eric J","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health , Boston, Massachussetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M","family":"Holland","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth N","family":"Olivier","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine, University of North Carolina , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3324-926X","authenticated-orcid":false,"given":"Charles L","family":"Daley","sequence":"additional","affiliation":[{"name":"Division of Mycobacterial and Respiratory Infections, National Jewish Health , Denver, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-131X","authenticated-orcid":false,"given":"Barry N","family":"Kreiswirth","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9143-8857","authenticated-orcid":false,"given":"Paul S","family":"Pottinger","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Allergy & Infectious Diseases, University of Washington School of Medicine , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3299-894X","authenticated-orcid":false,"given":"Robert A","family":"Bonomo","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland VA Medical Center, Case Western Reserve University , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Medicine, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]},{"name":"CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES) , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Pharmacology, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Biochemistry, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]},{"name":"Department of Proteomics and Bioinformatics, Case Western Reserve University School of Medicine , Cleveland, Ohio ,","place":["USA"]},{"name":"GRECC, Louis Stokes Cleveland Department of Veterans Affairs Medical Center , Cleveland, Ohio ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2026071623564431300_ciaf547-B1","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: a new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J Antimicrobial Chemother"},{"key":"2026071623564431300_ciaf547-B2","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.3390\/microorganisms9122527","article-title":"Mycobacterium abscessus genetic determinants associated with the intrinsic resistance to antibiotics","volume":"9","author":"Gorzynski","year":"2021","journal-title":"Microorganisms"},{"key":"2026071623564431300_ciaf547-B3","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1590\/0074-02760170080","article-title":"Lack of association between rrl and erm(41) mutations and clarithromycin resistance in Mycobacterium abscessus complex","volume":"112","author":"Carneiro","year":"2017","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2026071623564431300_ciaf547-B5","doi-asserted-by":"crossref","first-page":"e0219923","DOI":"10.1128\/spectrum.02199-23","article-title":"Characterization of in vitro resistance to linezolid in Mycobacterium abscessus","volume":"11","author":"Negatu","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026071623564431300_ciaf547-B6","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.aaf8156","article-title":"Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium","volume":"354","author":"Bryant","year":"2016","journal-title":"Science"},{"key":"2026071623564431300_ciaf547-B7","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diagmicrobio.2017.12.008","article-title":"Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease","volume":"90","author":"Choi","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026071623564431300_ciaf547-B8","first-page":"2000535","article-title":"Treatment of nontuberculous Mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2026071623564431300_ciaf547-B9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jac\/dkt410","article-title":"Characterization of broad-spectrum Mycobacterium abscessus class A beta-lactamase","volume":"69","author":"Soroka","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026071623564431300_ciaf547-B10","doi-asserted-by":"crossref","first-page":"e0117424","DOI":"10.1128\/aac.01174-24","article-title":"Durlobactam in combination with beta-lactams to combat Mycobacterium abscessus","volume":"69","author":"Shin","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B11","doi-asserted-by":"crossref","first-page":"15406","DOI":"10.1038\/s41598-023-42152-8","article-title":"Mycobacterium tuberculosis beta-lactamase variant reduces sensitivity to ampicillin\/avibactam in a zebrafish-Mycobacterium marinum model of tuberculosis","volume":"13","author":"van Alen","year":"2023","journal-title":"Sci Rep"},{"key":"2026071623564431300_ciaf547-B12","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.39.12.2620","article-title":"Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis?","volume":"39","author":"Chambers","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B13","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis","volume":"323","author":"Hugonnet","year":"2009","journal-title":"Science"},{"key":"2026071623564431300_ciaf547-B14","first-page":"1081","article-title":"Inhibition of beta-lactamases of mycobacteria by avibactam and clavulanate","volume":"72","author":"Soroka","year":"2017","journal-title":"J Antimicrobial Chemother"},{"key":"2026071623564431300_ciaf547-B15","doi-asserted-by":"crossref","first-page":"e0060924","DOI":"10.1128\/mbio.00609-24","article-title":"Synergistic effects of sulopenem in combination with cefuroxime or durlobactam against Mycobacterium abscessus","volume":"15","author":"Dousa","year":"2024","journal-title":"mBio"},{"key":"2026071623564431300_ciaf547-B16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1586\/eri.12.96","article-title":"Reappraising the use of beta-lactams to treat tuberculosis","volume":"10","author":"Kurz","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026071623564431300_ciaf547-B17","doi-asserted-by":"crossref","first-page":"30414","DOI":"10.1074\/jbc.M704286200","article-title":"Unexpected inhibition of peptidoglycan LD-transpeptidase from Enterococcus faecium by the beta-lactam imipenem","volume":"282","author":"Mainardi","year":"2007","journal-title":"J Biol Chem"},{"key":"2026071623564431300_ciaf547-B18","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nm.2120","article-title":"The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin","volume":"16","author":"Gupta","year":"2010","journal-title":"Nat Med"},{"key":"2026071623564431300_ciaf547-B19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/JB.00606-10","article-title":"The peptidoglycan of Mycobacterium abscessus is predominantly cross-linked by L,D-transpeptidases","volume":"193","author":"Lavollay","year":"2011","journal-title":"J Bacteriol"},{"key":"2026071623564431300_ciaf547-B20","doi-asserted-by":"crossref","first-page":"e00098-20","DOI":"10.1128\/AAC.00098-20","article-title":"Insights into the l,d-Transpeptidases and d,d-Carboxypeptidase of Mycobacterium abscessus: ceftaroline, imipenem, and novel diazabicyclooctane inhibitors","volume":"64","author":"Dousa","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/235426a0","article-title":"Targets of penicillin action in Escherichia coli","volume":"235","author":"Hartmann","year":"1972","journal-title":"Nature"},{"key":"2026071623564431300_ciaf547-B22","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1021\/bi00714a008","article-title":"Occurrence of D-alanyl-(D)-meso-diaminopimelic acid and meso-diaminopimelyl-meso-diaminopimelic acid interpeptide linkages in the peptidoglycan of Mycobacteria","volume":"13","author":"Wietzerbin","year":"1974","journal-title":"Biochemistry"},{"key":"2026071623564431300_ciaf547-B23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1432-1033.1974.tb03504.x","article-title":"Membrane-bound DD-carboxypeptidase and LD-transpeptidase of Streptococcus faecalis ATCC 9790","volume":"44","author":"Coyette","year":"1974","journal-title":"Eur J Biochem"},{"key":"2026071623564431300_ciaf547-B24","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/fmb-2016-0208","article-title":"Ldt(Mav2), a nonclassical transpeptidase and susceptibility of Mycobacterium avium to carbapenems","volume":"12","author":"Mattoo","year":"2017","journal-title":"Future Microbiol"},{"key":"2026071623564431300_ciaf547-B25","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1128\/JB.00239-08","article-title":"The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by L,D-transpeptidation","volume":"190","author":"Lavollay","year":"2008","journal-title":"J Bacteriol"},{"key":"2026071623564431300_ciaf547-B26","doi-asserted-by":"crossref","first-page":"e0117424","DOI":"10.1128\/aac.01174-24","article-title":"Durlobactam in combination with \u03b2-lactams to combat Mycobacterium abscessus","volume":"69","author":"Shin","year":"2025","journal-title":"Antimicrobial Agents Chemother"},{"key":"2026071623564431300_ciaf547-B27","doi-asserted-by":"crossref","first-page":"e0352921","DOI":"10.1128\/mbio.03529-21","article-title":"Inhibiting Mycobacterium abscessus cell wall synthesis: using a novel diazabicyclooctane beta-lactamase inhibitor to augment beta-lactam action","volume":"13","author":"Dousa","year":"2022","journal-title":"mBio"},{"key":"2026071623564431300_ciaf547-B28","doi-asserted-by":"crossref","first-page":"e02613-18","DOI":"10.1128\/AAC.02613-18","article-title":"Select beta-lactam combinations exhibit synergy against Mycobacterium abscessus in vitro","volume":"63","author":"Story-Roller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2180-14-75","article-title":"Comparative genomics for mycobacterial peptidoglycan remodelling enzymes reveals extensive genetic multiplicity","volume":"14","author":"Machowski","year":"2014","journal-title":"BMC Microbiol"},{"key":"2026071623564431300_ciaf547-B30","doi-asserted-by":"crossref","first-page":"706207","DOI":"10.3389\/fmicb.2021.706207","article-title":"Increased virulence of outer membrane porin mutants of Mycobacterium abscessus","volume":"12","author":"de Moura","year":"2021","journal-title":"Front Microbiol"},{"key":"2026071623564431300_ciaf547-B31","doi-asserted-by":"crossref","first-page":"e0067324","DOI":"10.1128\/aac.00673-24","article-title":"Evolution toward extremely high imipenem resistance in Mycobacterium abscessus outbreak strains","volume":"68","author":"Le Run","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B32","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1128\/AAC.05546-11","article-title":"The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance","volume":"56","author":"Schmalstieg","year":"2012","journal-title":"Antimicrobial Agents Chemother"},{"key":"2026071623564431300_ciaf547-B33","doi-asserted-by":"publisher","author":"McGowen","DOI":"10.1101\/2024.08.23.609441"},{"key":"2026071623564431300_ciaf547-B34","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jgar.2022.10.015","article-title":"Unraveling antibiotic resistance mechanisms in Mycobacterium abscessus: the potential role of efflux pumps","volume":"31","author":"Mudde","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"2026071623564431300_ciaf547-B35","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3389\/fmicb.2018.02273","article-title":"Mycobacterium abscessus and beta-lactams: emerging insights and potential opportunities","volume":"9","author":"Story-Roller","year":"2018","journal-title":"Front Microbiol"},{"key":"2026071623564431300_ciaf547-B36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/IDR.S239850","article-title":"Efflux pumps contribute to intrinsic clarithromycin resistance in clinical, Mycobacterium abscessus isolates","volume":"13","author":"Guo","year":"2020","journal-title":"Infect Drug Resist"},{"key":"2026071623564431300_ciaf547-B37","doi-asserted-by":"crossref","first-page":"102295","DOI":"10.1016\/j.tube.2022.102295","article-title":"Mab2780c, a TetV-like efflux pump, confers high-level spectinomycin resistance in mycobacterium abscessus","volume":"138","author":"Hurst-Hess","year":"2023","journal-title":"Tuberculosis (Edinb)"},{"key":"2026071623564431300_ciaf547-B38","doi-asserted-by":"crossref","first-page":"e0033021","DOI":"10.1128\/AAC.00330-21","article-title":"MAB_2355c confers macrolide resistance in Mycobacterium abscessus by ribosome protection","volume":"65","author":"Guo","year":"2021","journal-title":"Antimicrobial Agents Chemother"},{"key":"2026071623564431300_ciaf547-B39","doi-asserted-by":"crossref","first-page":"e1011318","DOI":"10.1371\/journal.ppat.1011318","article-title":"The cell envelope of Mycobacterium abscessus and its role in pathogenesis","volume":"19","author":"Parmar","year":"2023","journal-title":"PLoS Pathog"},{"key":"2026071623564431300_ciaf547-B40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1089\/mdr.2016.0047","article-title":"Biochemical characterization of beta-lactamases from Mycobacterium abscessus complex and genetic environment of the beta-lactamase-encoding gene","volume":"23","author":"Ramirez","year":"2017","journal-title":"Microb Drug Resist"},{"key":"2026071623564431300_ciaf547-B41","doi-asserted-by":"crossref","first-page":"e0139923","DOI":"10.1128\/aac.01399-23","article-title":"Comprehensive stability analysis of 13 beta-lactams and beta-lactamase inhibitors in in vitro media, and novel supplement dosing strategy to mitigate thermal drug degradation","volume":"68","author":"Zhou","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B42","doi-asserted-by":"crossref","first-page":"105795","DOI":"10.1016\/j.mimet.2019.105795","article-title":"Tween 80 induces a carbon flux rerouting in Mycobacterium tuberculosis","volume":"170","author":"Pietersen","year":"2020","journal-title":"J Microbiol Methods"},{"key":"2026071623564431300_ciaf547-B43","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1128\/AAC.00986-07","article-title":"Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria","volume":"52","author":"Greendyke","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B44","doi-asserted-by":"crossref","first-page":"e02895-18","DOI":"10.1128\/mBio.02895-18","article-title":"Dual beta-lactam combinations highly active against Mycobacterium abscessus complex in vitro","volume":"10","author":"Pandey","year":"2019","journal-title":"mBio"},{"key":"2026071623564431300_ciaf547-B45","doi-asserted-by":"crossref","first-page":"e00866-17","DOI":"10.1128\/AAC.00866-17","article-title":"Mycobacterium abscessus l,d-transpeptidases are susceptible to inactivation by carbapenems and cephalosporins but not penicillins","volume":"61","author":"Kumar","year":"2017","journal-title":"Antimicrobial Agents Chemother"},{"key":"2026071623564431300_ciaf547-B46","doi-asserted-by":"crossref","first-page":"e0079022","DOI":"10.1128\/aac.00790-22","article-title":"Strongly bactericidal all-oral beta-lactam combinations for the treatment of Mycobacterium abscessus lung disease","volume":"66","author":"Negatu","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B47","doi-asserted-by":"crossref","first-page":"106669","DOI":"10.1016\/j.ijantimicag.2022.106669","article-title":"In vitro effects of diazabicyclooctane beta-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex","volume":"60","author":"Misawa","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026071623564431300_ciaf547-B48","doi-asserted-by":"crossref","first-page":"e00733-19","DOI":"10.1128\/AAC.00733-19","article-title":"New beta-lactamase inhibitors nacubactam and zidebactam improve the in vitro activity of beta-lactam antibiotics against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrobial Agents Chemother"},{"key":"2026071623564431300_ciaf547-B49","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jac\/dku510","article-title":"beta-lactamase inhibition by avibactam in Mycobacterium abscessus","volume":"70","author":"Dubee","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026071623564431300_ciaf547-B50","doi-asserted-by":"crossref","first-page":"e02623-18","DOI":"10.1128\/AAC.02623-18","article-title":"In vitro activity of the new beta-lactamase inhibitors relebactam and vaborbactam in combination with beta-lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B51","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/jac\/dkx125","article-title":"Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes","volume":"72","author":"Rominski","year":"2017","journal-title":"J Antimicrobial Chemother"},{"key":"2026071623564431300_ciaf547-B52","doi-asserted-by":"crossref","first-page":"e0104624","DOI":"10.1128\/aac.01046-24","article-title":"Durlobactam to boost the clinical utility of standard of care beta-lactams against Mycobacterium abscessus lung disease","volume":"69","author":"Negatu","year":"2025","journal-title":"Antimicrobial Agents Chemother"},{"key":"2026071623564431300_ciaf547-B53","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1093\/infdis\/jiae601","article-title":"Imipenem pharmacokinetics\/pharmacodynamics in preclinical hollow fiber model, dose-finding in virtual patients, and clinical evidence of efficacy for Mycobacterium abscessus lung disease","volume":"231","author":"Singh","year":"2025","journal-title":"J Infect Dis"},{"key":"2026071623564431300_ciaf547-B54","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12941-025-00776-w","article-title":"Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model","volume":"24","author":"Vignaud","year":"2025","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2026071623564431300_ciaf547-B55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41429-020-00392-0","article-title":"Comparison of two-drug combinations, amikacin\/tigecycline\/imipenem and amikacin\/tigecycline\/clarithromycin against Mycobacteroides abscessus subsp. abscessus using the in vitro time-kill assay","volume":"74","author":"Portell-Buj","year":"2021","journal-title":"J Antibiot (Tokyo)"},{"key":"2026071623564431300_ciaf547-B56","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jconrel.2020.08.045","article-title":"Nanoscale drug delivery systems for controllable drug behaviors by multi-stage barrier penetration","volume":"331","author":"Wang","year":"2021","journal-title":"J Control Release"},{"key":"2026071623564431300_ciaf547-B57","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/civ495","article-title":"Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)","volume":"61","author":"Evans","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026071623564431300_ciaf547-B58","doi-asserted-by":"crossref","first-page":"ofad312","DOI":"10.1093\/ofid\/ofad312","article-title":"Eradicating pulmonary Mycobacterium abscessus: the promise of dual beta-Lactam Therapy","volume":"10","author":"Alahmdi","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026071623564431300_ciaf547-B59","doi-asserted-by":"crossref","first-page":"e00614-19","DOI":"10.1128\/AAC.00614-19","article-title":"Synergistic efficacy of beta-lactam combinations against Mycobacterium abscessus pulmonary infection in mice","volume":"63","author":"Story-Roller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B60","doi-asserted-by":"crossref","first-page":"e01206-17","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B61","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3201\/eid2908.230317","article-title":"Mycobacterium abscessus meningitis associated with stem cell treatment during medical tourism","volume":"29","author":"Wolf","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"2026071623564431300_ciaf547-B62","doi-asserted-by":"crossref","first-page":"ofae631-1672","DOI":"10.1093\/ofid\/ofae631.1672","article-title":"Kreiswirth P-1503. Dual \u03b2-lactam approach for treatment of Mycobacterium abscessus infections in adults\u2014results in 19 patients","volume":"12","author":"Kalyatanda","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2026071623564431300_ciaf547-B63","doi-asserted-by":"crossref","first-page":"e0031924","DOI":"10.1128\/aac.00319-24","article-title":"Dual beta-lactam for treatment of pulmonary Mycobacterium abscessus in a child","volume":"68","author":"Becken","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026071623564431300_ciaf547-B64","first-page":"e40993","article-title":"A 40-year-old female with Mycobacterium abscessus successfully treated with a dual Beta-lactam combination","volume":"15","author":"Moguillansky","year":"2023","journal-title":"Cureus"},{"key":"2026071623564431300_ciaf547-B65","first-page":"e65112","article-title":"Combination of imipenem-cilastatin-relebactam and amoxicillin in the antibiotic regimen in two cases of Mycobacterium abscessus lung infection","volume":"16","author":"Vogiatzoglou","year":"2024","journal-title":"Cureus"},{"key":"2026071623564431300_ciaf547-B66","doi-asserted-by":"crossref","first-page":"10360","DOI":"10.1038\/s41467-024-54666-4","article-title":"Use of epigenetically modified bacteriophage and dual beta-lactams to treat a Mycobacterium abscessus sternal wound infection","volume":"15","author":"Cristinziano","year":"2024","journal-title":"Nat Commun"},{"key":"2026071623564431300_ciaf547-B67","doi-asserted-by":"crossref","first-page":"e00056-25","DOI":"10.1128\/asmcr.00056-25","article-title":"Case report of peritoneal dialysis-associated peritonitis caused by Mycobacterium abscessus in a child, successfully treated with dual \u03b2-lactam combination therapy","volume":"1","author":"Shirley","year":"2025","journal-title":"ASM Case Reports"},{"key":"2026071623564431300_ciaf547-B68","doi-asserted-by":"crossref","first-page":"e00087-24","DOI":"10.1128\/asmcr.00087-24","article-title":"Successful treatment of macrolide-resistant Mycobacterium abscessus infection using multi-drug regimens including dual \u03b2-lactams and phage therapy: case reports in two children","volume":"1","author":"Shimamura","year":"2025","journal-title":"ASM Case Reports"},{"key":"2026071623564431300_ciaf547-B69","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria","volume":"25","author":"Brown-Elliott","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2026071623564431300_ciaf547-B70","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease","volume":"161","author":"Griffith","year":"2022","journal-title":"Chest"},{"key":"2026071623564431300_ciaf547-B71","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41598-020-57844-8","article-title":"Effect of amoxicillin in combination with imipenem-relebactam against Mycobacterium abscessus","volume":"10","author":"Lopeman","year":"2020","journal-title":"Sci Rep"},{"key":"2026071623564431300_ciaf547-B72","doi-asserted-by":"crossref","first-page":"a027029","DOI":"10.1101\/cshperspect.a027029","article-title":"Aminoglycosides: an overview","volume":"6","author":"Krause","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026071623564431300_ciaf547-B73","doi-asserted-by":"crossref","first-page":"1901300","DOI":"10.1183\/13993003.01300-2019","article-title":"Preliminary validation of the NTM module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease","volume":"55","author":"Henkle","year":"2020","journal-title":"Eur Respir J"},{"key":"2026071623564431300_ciaf547-B74","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.chest.2020.08.2055","article-title":"Development of drugs for nontuberculous mycobacterial disease: clinicians\u2019 interpretation of a US Food and Drug Administration Workshop","volume":"159","author":"Flume","year":"2021","journal-title":"Chest"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf547\/64454857\/ciaf547.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/e135\/64454857\/ciaf547.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/e135\/64454857\/ciaf547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:56:55Z","timestamp":1784260615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/1\/e135\/8269231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2026,2,9]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf547","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,15]]},"published":{"date-parts":[[2025,9,30]]}}}